Compare SPDR Gold Trust (GLD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs ResMed Inc. — how do they compare? SPDR Gold Trust trades at $403.5, while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while SPDR Gold Trust pays none, and SPDR Gold Trust is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| GLD | RMD | |
|---|---|---|
52-Week High | $495.90 | $293.73 |
52-Week Low | $305.27 | $182.82 |
Market Cap | — | $32.61B |
Sector | — | Health |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD trades at $404.93, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent news highlights gold's strength amid cooling inflation and geopolitical tensions, with spot gold reaching multi-month highs. The ETF shows momentum but faces resistance near $405.
The outlook remains positive due to safe-haven demand and central bank buying, though high RSI suggests near-term consolidation risks. Upside potential exists toward $4,500, but investors should monitor inflation data and Fed policy for directional cues amid elevated volatility.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
